MEI Pharma reported no revenue in QQ3 2024, recording a net loss of $9.13 million for the quarter and an operating loss of $9.83 million. R&D expenditure totaled $5.22 million, with G&A expense of $4.61 million and a small depreciation expense of $0.086 million, yielding a negative EBITDA of $9.74 million. The company funded operations during the quarter with a $11.66 million financing activity, while operating cash flow remained negative at approximately $2.93 million. Balance sheet highlights include $56.6 million in cash and short-term investments and total liabilities of $20.23 million against $51.03 million in stockholders’ equity, suggesting a solid liquidity position relative to current obligations but a fragile earnings profile given ongoing clinical development. The near-term outlook centers on execution of late-stage and mid-stage oncology programs (notably Zandelisib in relapsed/refractory follicular lymphoma and Vorucilib in B-cell malignancies) and potential strategic collaborations to monetize pipeline value. Investors should monitor upcoming readouts, regulatory steps, and any additional financing activity, as management guidance is not explicitly disclosed for QQ3 2024.